Generics 5

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Gliclazide manufacturers

5 products found

Filters

Filters

Filters , active

Country of origin : Malaysia

Clear all

5 products found

gliclazide

Tablets 80 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Malaysia
GMP approvals
EU GMP
Manufacturer #20853
The company’s mission is to invest in and operate businesses that restore health and enhances the lives of those they serve. Healthcare professionals use medicines and diagnostic devices to treat and manage infections, cardiovascular, metabolic, gastroenterological, rheumatic conditions, and more.

Manufacturer usually replies in 4 days

gliclazide

Tablets, modified release (MR) 30 mg, 60 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Malaysia
GMP approvals
FDA, WHO, PICS, MY, US
Unavailable markets
Brunei , Malaysia , Singapore , United States
Registered in
Malaysia
Available for
Licensing with supply, Distribution only, Technology transfer
Manufacturer #25654
This company is a global pharmaceutical player with over three decades of experience, focusing primarily on oncology products. They boast manufacturing facilities in Malaysia, Uzbekistan, and Pakistan, all adhering to stringent regulatory standards like USFDA, NPRA, PIC/S, and UAE MoHAP. Their product portfolio includes prescription medications like Pazopanib Tablets, Trametinib, Sunitinib, and Gefitinib, among others. They also offer over-the-counter drugs and possess Halal certifications for select products. The company emphasizes R&D, with a dedicated oncology center in Malaysia, and engages in strategic collaborations for in-licensing, out-licensing, tech transfer, contract development, and manufacturing.

Manufacturer usually replies in 3 days

gliclazide

Tablets 80 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Malaysia
GMP approvals
EU GMP, PICS
Manufacturer #20652
It is a leading EU GMP-certified pharmaceutical company. It is focused on developing, manufacturing, and marketing branded off-patent pharmaceuticals, medical devices, and consumer healthcare products. The products are exported to countries in Asia Pacific, Africa, and the Middle East. Presence in over 22 countries. They have an experience of more than 50 years of in Southeast Asia.

Manufacturer usually replies in 5 days

Want to see all 5 products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

GLICLAZIDE

Gliclazide is an anti-diabetic medication for the treatment of diabetes mellitus type 2. Gliclazide controls hyperglycemia in gliclazide-responsive diabetes mellitus of stable, mild, non-ketosis prone, type 2 diabetes. As an oral antihyperglycemic agent, it is used for the treatment of non-insulin-dependent diabetes mellitus. It has been classified differently according to its drug properties based on its chemical structure. When launched it belonged to the first-generation of sulfonylurea due to the structural presence of a sulfonamide group able to release a proton and the presence of one aromatic group. However, further studies have shown that Gliclazide is a second-generation sulfonylurea, because it has higher potency and a shorter half-life. Gliclazide is sold under the brand names Diamicron, Diaprel, Azukon, and others. Gliclazide was first patented in 1966 and approved for medical use in 1972. Due to its efficacy and use around the world, it has been listed on the World Health Organization's List of Essential Medicines. Gliclazide is not available for sale in the United States.

Forms and dose:

Gliclazide is available as a tablet and extended-release tablet. In the treatment of type 2 diabetes, the total daily dose recommended varies from 40-320mg. The dose is increased or decreased depending on the response to the therapy. The initial adult dose starts with 40-80mg daily. This can be increased until adequate control is reached. Please note that any single dose should not exceed 160mg. if a patient feels that they need higher doses, it is recommended to take medicine twice a day instead.

The price of Gliclazide:

In India, the lowest price consumers can pay for an 80 mg pill is $0.33. The same supply can cost as low as USD64 for the same supply for medicine.

How does it work?

Gliclazide is in the sulfonylurea family of medications. Its actions increase the release of insulin. It binds to the β cell sulfonylurea receptor subsequently blocking the ATP sensitive potassium channels. The process leads to the closing of channels that leads to a resulting decrease in potassium efflux. This eventually leads to depolarization of the β cells. In the next step, it opens voltage-dependent calcium channels in the β cell resulting in activation of calmodulin. The result of this process is exocytosis of insulin-containing secretory granules.

Finding Gliclazide Manufacturers and Suppliers

The best way to find and gain access to Gliclazide manufacturers and Gliclazide suppliers is to use Pipelinepharma's global B2B online marketplace for medicines and other pharmaceuticals. Normally, finding trusted manufacturers and supplies of specific drugs like Gliclazide can be a time-consuming challenge, but with Pipelinepharma's simple search engine and network of proven partners, the whole process becomes a lot easier. All you need to do to get started is to make use of our integrated search engine and start looking for suppliers or manufacturers of Gliclazide to work with. You can fine-tune your search results using various filters too, letting you search for Gliclazide from specific countries, for example.

Interested in becoming a subscriber?

Please provide the following information to receive an offer tailored to your business needs

  1. Number of company users for the subscription
  2. The rough number of products you would like to source in the 12 months
  3. Target market(s) for commercialisation